Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Castagna

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Bone Marrow Transplantation|November 24, 2015
Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamideL Castagna, S Bramanti, S Furst, et al.
Bone Marrow Transplantation|May 4, 2017
Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphomaL Castagna, S Bramanti, R Devillier, et al.
Bone Marrow Transplantation|January 17, 2017
Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphomaL Castagna, S Bramanti, R Devillier, et al.
Bone Marrow Transplantation|January 10, 2017
Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO)E Todisco, F Ciceri, C Boschini, et al.
Bone Marrow Transplantation|March 22, 2016
The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamideR Crocchiolo, L Castagna, S Furst, et al.
British Journal of Haematology|November 9, 2021
Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMTG Gutiérrez-García, C Martínez, A Boumendil, et al.
Leukemia|March 2, 2012
Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patientsA Rambaldi, A Bacigalupo, R Fanin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2013
Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantationC Martínez, C Canals, B Sarina, et al.
Bone Marrow Transplantation|January 10, 2017
Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular TherapyJ Gauthier, L Castagna, F Garnier, et al.
British Journal of Cancer|October 24, 2013
Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessmentU Thiel, E Koscielniak, F Blaeschke, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Bone Marrow Transplantation|November 24, 2015
Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamideL Castagna, S Bramanti, S Furst, et al.
Bone Marrow Transplantation|May 4, 2017
Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphomaL Castagna, S Bramanti, R Devillier, et al.
Bone Marrow Transplantation|January 17, 2017
Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphomaL Castagna, S Bramanti, R Devillier, et al.
Bone Marrow Transplantation|January 10, 2017
Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO)E Todisco, F Ciceri, C Boschini, et al.
Bone Marrow Transplantation|March 22, 2016
The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamideR Crocchiolo, L Castagna, S Furst, et al.
British Journal of Haematology|November 9, 2021
Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMTG Gutiérrez-García, C Martínez, A Boumendil, et al.
Leukemia|March 2, 2012
Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patientsA Rambaldi, A Bacigalupo, R Fanin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2013
Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantationC Martínez, C Canals, B Sarina, et al.
Bone Marrow Transplantation|January 10, 2017
Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular TherapyJ Gauthier, L Castagna, F Garnier, et al.
British Journal of Cancer|October 24, 2013
Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessmentU Thiel, E Koscielniak, F Blaeschke, et al.
Pageof 10